Statins

Statins are cholesterol-lowering medications. More specifically, they lower LDL cholesterol by blocking HMG-CoA reductase, a liver enzyme involved in cholesterol production, and they’ve become one of the most studied drug classes in modern medicine because atherosclerotic cardiovascular disease is still one of the main ways people get sick and die. The basic case for them isn’t mysterious: lowering LDL changes cardiovascular risk in a measurable way. The reason they stay controversial anyway is that the benefit depends a lot on who is taking them, while the side effects and tradeoffs land on an individual body, not on a population curve.

What statins are for

The cleanest use case is established cardiovascular disease. If somebody has already had a heart attack, ischemic stroke, stent, bypass, or known coronary or peripheral arterial disease, statins are standard because the baseline event risk is already high and the benefit isn’t subtle. The next group is people at clearly elevated risk who haven’t had an event yet, for example very high LDL levels, diabetes in the right context, or a risk calculation high enough that the likely cardiovascular benefit outweighs the downsides. That’s the frame that matters. Statins aren’t vitamins and they aren’t moral upgrades. They’re risk-reduction drugs, and the higher the baseline risk, the easier the case is to make.

What the benefit actually looks like

The broad evidence base says statins reduce major vascular events, and that finding has held up across very large randomized datasets. In the Cholesterol Treatment Trialists meta-analysis of 27 randomized trials, each 1.0 mmol/L drop in LDL cholesterol was associated with a real reduction in major vascular events even in people at relatively low baseline vascular risk (CTT Collaborators 2012, PMID 22607822). More recent primary-prevention evidence reviews for the USPSTF landed in basically the same place: in adults at increased cardiovascular risk but without prior cardiovascular events, statin therapy reduces cardiovascular events and is associated with a modest reduction in all-cause mortality as well (Chou 2022, PMID 35997724).

The absolute benefit isn’t the same for everyone, though. If baseline risk is high, preventing one event out of a hundred or a few out of a hundred over several years matters a lot. If baseline risk is low, the same relative risk reduction may still be statistically real, but fewer actual bad outcomes are being prevented in absolute terms. So the real question isn’t just “do statins work?” They do. The real question is whether they’re worth it for this specific person at this specific level of risk.

The side effects people ask about first

Muscle symptoms are the main reason the conversation gets messy. Some people get aches, heaviness, cramping, or a washed-out feeling after starting a statin, and some do improve when the drug is stopped or changed. The severe version, rhabdomyolysis with dangerous muscle breakdown, is real but rare. The harder part is that ordinary muscle pain is also common in adults who are aging, exercising, carrying extra weight, or taking other medications, so every ache after a statin start isn’t automatically a statin injury.

The nocebo problem is real here too. In blinded trials, muscle-symptom rates are usually much closer between statin and placebo than they are in open-label real-world use, which suggests that expectation explains part of what gets blamed on the drug. The drucebo analysis, looking at blinded versus unblinded statin studies, estimated that a substantial share of reported statin-associated muscle symptoms may be driven by expectation rather than pharmacology alone (Howard 2018, PMID 30311434). That doesn’t mean all muscle symptoms are imaginary, it just means this is one of those classes where both things can be true at once: genuine adverse effects exist, and symptom attribution gets noisy fast.

The useful question is not whether statins are good or bad. The useful question is whether your actual risk justifies the trade.

Other real downsides

The diabetes issue is one of the better-established tradeoffs. Randomized-trial meta-analyses have shown a small increase in new-onset diabetes with statin therapy, especially in people who were already metabolically close to that line and in those on more intensive treatment. The older collaborative meta-analysis found a modest increase in incident diabetes across randomized statin trials (Sattar 2010, PMID 20167359), and the newer individual-participant-data meta-analysis confirmed that statins slightly increase diagnoses of diabetes and worsen glycemia while also making the same broader point clinicians keep coming back to: those glucose effects are small relative to the overall cardiovascular-risk reduction seen in the same trials (CTT Collaborators 2024, PMID 38554713).

Liver enzyme elevations can happen, but serious liver injury from statins is uncommon. The old habit of routine periodic liver-function monitoring was backed off because it wasn’t catching much of clinical value in most patients. There are also class-specific cautions around pregnancy, drug interactions, and rare immune-mediated muscle injury. Those issues aren’t fake, but they aren’t the main story for most patients either. Most people who tolerate statins don’t develop catastrophic toxicity. The more common real-world problem is milder side effects, uncertainty about whether the drug is causing them, and people stopping treatment without a clear re-challenge or alternative plan.

What about memory and cognition?

This is the part that keeps statins relevant to a psychiatry-adjacent audience. In 2012 the FDA required labeling changes noting rare postmarketing reports of cognitive impairment, including memory loss, forgetfulness, and confusion, generally described as non-serious and reversible after stopping the statin. That’s real and it shouldn’t just get quietly dropped from the conversation. At the same time, randomized-trial evidence hasn’t shown a clear signal that statins broadly impair cognition. In the 2015 meta-analysis of randomized controlled trials focused on cognitive outcomes, statin therapy wasn’t associated with measurable cognitive harm on pooled neuropsychological testing data (Ott 2015, PMID 25575908).

The fair read is that large trial data haven’t shown population-level cognitive injury, but rare patient-level complaints have been around long enough that you can’t just wave them away either. If somebody starts a statin and then notices a clear cognitive change that reverses on stopping and comes back on rechallenge, that deserves to be taken seriously even if the average trial participant did fine. Population reassurance and individual tolerability aren’t the same question.

Where the arguments usually are

The loudest disagreements are mostly about primary prevention, not about whether statins help somebody who already has clear atherosclerotic disease. In higher-risk patients, the mainstream evidence case is strong. In lower-risk patients, older adults with frailty, or people whose symptoms after starting a statin feel real enough to matter, the conversation gets more individualized. The 2021 BMJ systematic review of primary-prevention adverse events found that some harms, including self-reported muscle symptoms, liver dysfunction, renal insufficiency, and eye conditions, varied by statin type or dose, while overall major cardiovascular-event reduction still outweighed those increases at the population level (Cai 2021, PMID 34261627). That’s why there isn’t a one-line answer that fits everybody.

There’s also a style problem in how statins get prescribed. In some settings they’re discussed like an automatic checkbox rather than a medication with a real benefit-risk conversation attached to it. That doesn’t make statins bad drugs, it just means a good drug can still get prescribed on autopilot. The right conversation covers actual risk numbers, what benefit you’re realistically expecting, which side effects matter most to that guy, what to do if symptoms show up, and what the backup plan is if the first statin doesn’t work.

The bottom line

Statins are legitimate cardiovascular risk-reduction drugs with one of the largest evidence bases in medicine. They clearly reduce major vascular events, especially when baseline cardiovascular risk is already meaningful, and that’s why they remain standard therapy. They also carry real downsides: muscle symptoms for some patients, a small diabetes tradeoff, rare but important safety issues, and a patient-level cognition argument where broad trial data look reassuring but some individuals still report problems that clinicians shouldn’t dismiss out of hand. If you’re trying to decide whether a statin makes sense, the useful question is whether the cardiovascular benefit for you outweighs the downsides for you, and that call gets a lot cleaner when it’s made with actual risk numbers instead of vibes or ideology.

Sources

1. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-590. PMID 22607822.
2. Chou R, Cantor A, Dana T, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022;328(8):754-771. PMID 35997724.
3. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742. PMID 20167359.
4. Cholesterol Treatment Trialists’ Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024. PMID 38554713.
5. Ott BR, Daiello LA, Dahabreh IJ, et al. Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Gen Intern Med. 2015;30(3):348-358. PMID 25575908.
6. Howard JP, Wood FA, Finegold JA, et al. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. Eur J Prev Cardiol. 2021;28(11):1210-1217. PMID 30311434.
7. Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021;374:n1537. PMID 34261627.
8. U.S. Food and Drug Administration. 2012 statin safety labeling changes, including rare postmarketing reports of cognitive impairment described in statin labeling and related FDA safety communication materials. FDA Drug Safety Communications.